Oxethazaine Precautions, Details, Emergency, warnings, Fda, api, Active Pharmaceutical Ingredients, Symptoms, Exporters, Oxethazaine, Causes, Health Centres, Molecular Formula C28H41N3O3, Molecular Weight 467.65, CAS Registry Number 126-27-2, Importers, Generic Products, bulk drugs, Raw Material Exporters, Research, Taj Pharmaceuticals LTd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Oxethazaine taj Pharmaceuticals Ltd.

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Oxethazaine Manufacturers in India Suppliers Oxethazaine Exporters Distributors Oxethazaine api active pharmaceuticals ingredients Oxethazaine manufacturers Side Effects bulk drugs raw material Oxethazaine companies Side Effects Importers Oxethazaine Oxethazaine Exporters Oxethazaine exporters FDA Oxethazaine DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Oxethazaine manufacturing pharmaceutical drugs pharmaceutical intermediates Oxethazaine pharmaceutical chemicals pharmaceutical raw materials Oxethazaine active pharmaceutical ingredients Oxethazaine committee active pharmaceutical ingredients manufacturer Oxethazaine Active Pharmaceutical Ingredients manufacturer Oxethazaine exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Oxethazaine, Oxethazaine manufacturer India, Oxethazaine product, Oxethazaine products, Api preparation, Certificate of Analysis API manufacturer product, Oxethazaine anti ulcer product, Certificate of Origin COA Oxethazaine COS Oxethazaine, pharmaceutical generic, pharmaceutical drug, medical, Oxethazaine pharma healthcare, pharma patents, contract MSDS manufacturing Trader Oxethazaine pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Oxethazaine expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Oxethazaine DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Oxethazaine ingredients, api, HIV Oxethazaine, tablets, capsules, syrup & protein Oxethazaine powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Oxethazaine gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Oxethazaine WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

Oxethazaine

HOME >> API >> API List 3 >> Oxethazaine >> Precautions

PRECAUTIONS
Oxethazaine CAS Registry Number 126-27-2

The use of magnesium-containing antacids in patients with mild to moderate renal impairment should be carefully monitored due to a possible increased danger of hypermagnesaemia.
In patients with chronic renal failure, hyperaluminaemia may occur. Encephalopathy and dementia may occur in patients with poor renal function or patients on dialysis, due to an increase in plasma concentration of aluminium.
Hypophosphataemia may occur with prolonged administration or large doses of aluminium-containing antacids (except aluminium phosphate) especially in patients with an inadequate dietary intake of phosphorus.
Laboratory Tests –Serum phosphate levels should be monitored at monthly or bi-monthly intervals in patients on maintenance haemodialysis who are receiving chronic antacid therapy.
Use in children –The safety and effectiveness of Oxethazaine in children has not been established.
Drug Interactions –The rate and/or extent of absorption of many medicines may be increased or decreased. Therefore, medication should not be taken within one to two hours of Oxethazaine .
An incomplete list of substances for which the above statement has been shown to apply includes: tetracycline, iron salts, isoniazid, ethambutol, some anti-muscarinic drugs, benzodiazepines, phenothiazines ranitidine, indomethacin, phenytoin, nitrofurantoin, Vitamin A, fluoride and phosphate. An increase in the plasma level of quinidine and possible toxicity may result it alkalisation of the urine occurs following antacid therapy.

Pregnancy: A reproduction study performed in rabbits revealed no evidence of harm to the fetus. There are, however, no adequate or well-controlled studies in pregnant women. Use during pregnancy if the benefits outweigh the potential risks.

Lactation: It is not known if Oxethazaine is excreted in breast milk. Because many drugs are excreted in breast milk, a decision should be made whether to discontinue nursing or to discontinue Oxethazaine , taking into account the importance of the drug to the mother and the potential risk to the infant.

Children: The safety and effectiveness of Oxethazaine in children have not been established. Therefore this product is recommended for adult use only.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS >>

INTERACTION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.